YTHDF1 and colorectal carcinoma: Functionally, inhibition of YTHDF1 not only sensitizes MSI-H CRC to PD-1 blockade but also overcomes the intrinsic resistance of MSS CRC, underscoring YTHDF1 as a potential immunotherapeutic target (59).